High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis

Increased serum levels of soluble CD163 in patients with scleroderma

(2012) Kazuhiro Shimizu et al.   CLINICAL RHEUMATOLOGY

Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: Detoxifying mechanisms and potential therapeutic options

(2012) Julio Madrigal-Matute et al.   THROMBOSIS AND HAEMOSTASIS

EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research

(2011) C. Beyer et al.   ANNALS OF THE RHEUMATIC DISEASES

Heterogeneity of Macrophage Populations and Expression of Galectin-3 in Cutaneous Wound Healing in Rats

(2011) V. Juniantito et al.   JOURNAL OF COMPARATIVE PATHOLOGY

Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163

(2010) Anders Etzerodt et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Serum levels of soluble CD163 in patients with systemic sclerosis

(2010) Wakana Nakayama et al.   RHEUMATOLOGY INTERNATIONAL

Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis

(2010) Nobuyo Higashi-Kuwata et al.   ARTHRITIS RESEARCH & THERAPY

The CD163-expressing macrophages recognize and internalize TWEAK

(2009) Juan A. Moreno et al.   ATHEROSCLEROSIS

Innate immunity and inflammation in systemic sclerosis

(2009) Robert Lafyatis et al.   CURRENT OPINION IN RHEUMATOLOGY

Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts

(2009) Nobuyuki Ebihara et al.   EXPERIMENTAL EYE RESEARCH

Elevated Circulating TWEAK Levels in Systemic Sclerosis: Association with Lower Frequency of Pulmonary Fibrosis

(2009) K. YANABA et al.   JOURNAL OF RHEUMATOLOGY

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease

(2008) Arnold E. Postlethwaite et al.   ARTHRITIS AND RHEUMATISM

No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies

(2008) Timothy S. Zheng et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting

(2008) Jeffrey A. Winkles   NATURE REVIEWS DRUG DISCOVERY